Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection
Aim: to evaluate the efficacy and safety of convalescent plasma therapy for patients with severe SARS-CoV-2 infection.Materials and methods: the study included 64 patients with laboratory-confirmed severe new coronavirus infection. The control group consisted of 58 patients who, in addition to stand...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2022-04-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/1308 |
| _version_ | 1826557788173631488 |
|---|---|
| author | D. V. Lavrenchuk K. V. Zhdanov K. V. Kozlov O. V. Mal’cev V. V. Gordienko K. V. Kas’janenko A. V. Kushnir I. A. Vorob’jov A. M. Ivanov V. Nю Vil’janinov M. E. Meshkova Yu. V. Nikitin E. B. Masalov |
| author_facet | D. V. Lavrenchuk K. V. Zhdanov K. V. Kozlov O. V. Mal’cev V. V. Gordienko K. V. Kas’janenko A. V. Kushnir I. A. Vorob’jov A. M. Ivanov V. Nю Vil’janinov M. E. Meshkova Yu. V. Nikitin E. B. Masalov |
| author_sort | D. V. Lavrenchuk |
| collection | DOAJ |
| description | Aim: to evaluate the efficacy and safety of convalescent plasma therapy for patients with severe SARS-CoV-2 infection.Materials and methods: the study included 64 patients with laboratory-confirmed severe new coronavirus infection. The control group consisted of 58 patients who, in addition to standard therapy, received a transfusion of plasma from donors who had recovered from COVID-19. The effectiveness of immune plasma was assessed by the duration of fever, the level of oxygen (SpO2 %) in dynamics, the detection of SARSCoV-2 RNA in nasopharyngeal and oropharyngeal swabs using PCR method in dynamics, as well as by the dynamics of blood tests results. Adverse events (any medically adverse events that occurred after immune plasma transfusion) were recorded as safety criteria.Results: patients who received convalescent plasma, showed a significantly shorter period of SARS-CoV-2 replication compared with the control group. The use of immune plasma did not have a statistically significant effect on the duration of the fever, as well as the dynamics of blood oxygenation. Also, there were no significant differences compared with the control group when assessing blood tests parameters.Conclusion: The use of COVID-19 convalescent plasma to treat severe COVID-19 did not show significant clinical effect but reduced the period of viral replication. It also showed no unexpected or serious adverse events. |
| first_indexed | 2024-03-12T10:00:34Z |
| format | Article |
| id | doaj.art-a600178f4e6943548ee2160a7f4dc195 |
| institution | Directory Open Access Journal |
| issn | 2072-6732 |
| language | Russian |
| last_indexed | 2025-03-14T08:34:09Z |
| publishDate | 2022-04-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj.art-a600178f4e6943548ee2160a7f4dc1952025-03-02T13:00:34ZrusJournal InfectologyЖурнал инфектологии2072-67322022-04-01141535910.22625/2072-6732-2022-14-1-53-59969Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infectionD. V. Lavrenchuk0K. V. Zhdanov1K. V. Kozlov2O. V. Mal’cev3V. V. Gordienko4K. V. Kas’janenko5A. V. Kushnir6I. A. Vorob’jov7A. M. Ivanov8V. Nю Vil’janinov9M. E. Meshkova10Yu. V. Nikitin11E. B. Masalov12Military Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovAim: to evaluate the efficacy and safety of convalescent plasma therapy for patients with severe SARS-CoV-2 infection.Materials and methods: the study included 64 patients with laboratory-confirmed severe new coronavirus infection. The control group consisted of 58 patients who, in addition to standard therapy, received a transfusion of plasma from donors who had recovered from COVID-19. The effectiveness of immune plasma was assessed by the duration of fever, the level of oxygen (SpO2 %) in dynamics, the detection of SARSCoV-2 RNA in nasopharyngeal and oropharyngeal swabs using PCR method in dynamics, as well as by the dynamics of blood tests results. Adverse events (any medically adverse events that occurred after immune plasma transfusion) were recorded as safety criteria.Results: patients who received convalescent plasma, showed a significantly shorter period of SARS-CoV-2 replication compared with the control group. The use of immune plasma did not have a statistically significant effect on the duration of the fever, as well as the dynamics of blood oxygenation. Also, there were no significant differences compared with the control group when assessing blood tests parameters.Conclusion: The use of COVID-19 convalescent plasma to treat severe COVID-19 did not show significant clinical effect but reduced the period of viral replication. It also showed no unexpected or serious adverse events.https://journal.niidi.ru/jofin/article/view/1308convalescent plasmanovel coronavirus infectioncovid-19sars-cov-2 |
| spellingShingle | D. V. Lavrenchuk K. V. Zhdanov K. V. Kozlov O. V. Mal’cev V. V. Gordienko K. V. Kas’janenko A. V. Kushnir I. A. Vorob’jov A. M. Ivanov V. Nю Vil’janinov M. E. Meshkova Yu. V. Nikitin E. B. Masalov Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection Журнал инфектологии convalescent plasma novel coronavirus infection covid-19 sars-cov-2 |
| title | Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection |
| title_full | Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection |
| title_fullStr | Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection |
| title_full_unstemmed | Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection |
| title_short | Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection |
| title_sort | clinical efficacy and safety of convalescent plasma therapy for patients with sars cov 2 infection |
| topic | convalescent plasma novel coronavirus infection covid-19 sars-cov-2 |
| url | https://journal.niidi.ru/jofin/article/view/1308 |
| work_keys_str_mv | AT dvlavrenchuk clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT kvzhdanov clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT kvkozlov clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT ovmalcev clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT vvgordienko clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT kvkasjanenko clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT avkushnir clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT iavorobjov clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT amivanov clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT vnûviljaninov clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT memeshkova clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT yuvnikitin clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection AT ebmasalov clinicalefficacyandsafetyofconvalescentplasmatherapyforpatientswithsarscov2infection |